Matches in SemOpenAlex for { <https://semopenalex.org/work/W4249496640> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- W4249496640 endingPage "3729" @default.
- W4249496640 startingPage "3729" @default.
- W4249496640 abstract "3729 Background: Irinotecan based regimens are the standard 1st line treatment for MCRC because the other promising agent oxaliplatin is commercially unavailable in Turkey. Oxaliplatin, 5-FU and calcium leucovorine (FOLFOX4) has been reported to be one of the promising treatment options for irinotecan resistant tumors. We want to report our experience of the patients who received FOLFOX4 after progression on irinotecan based combination chemotherapy. Methods: All patients (n=17) with MCRC who received FOLFOX4 were collected retrospectively. Results: Nine (52.9%) patients were male and median age was 59 years (range 50–73). Two (11.8%) had stage II, 8 (47.1%) had stage III disease before relapse and 7 (41.2%) had stage IV disease at presentation. Median time to progression (TTP) on 1st line chemotherapy for metastatic disease was 6 months. Twelve patients (70.6%) received FOLFOX4 as 2nd line and 5 patients (29.4%) as 3rd line treatment. The TTP was 3 months and median overall survival (OS) was 22 months. There was no statistically significant difference in TTP or OS in between the patients who got FOLFOX4 as 2nd versus 3rd line treatment. TTP was 3 months (95% CI: 2–4) and 4±1 months (95% CI: 3–5) respectively, p=0.48. OS was 32±5 months (95% CI: 23–41) and 19±3 months (95% CI: 14–24) respectively, p=0.146. Conclusion: The benefit of FOLFOX4 in metastatic colorectal cancer patients who progresses after infusional 5-FU and irinotecan containing combination regimens is limited. No significant financial relationships to disclose." @default.
- W4249496640 created "2022-05-12" @default.
- W4249496640 creator A5017461185 @default.
- W4249496640 creator A5018888045 @default.
- W4249496640 creator A5039996765 @default.
- W4249496640 creator A5058524932 @default.
- W4249496640 creator A5064011743 @default.
- W4249496640 creator A5078640497 @default.
- W4249496640 creator A5088372569 @default.
- W4249496640 date "2004-07-15" @default.
- W4249496640 modified "2023-09-26" @default.
- W4249496640 title "FOLFOX4 in metastatic colorectal cancer (MCRC) patients who progressed after infusional 5-FU/irinotecan based combination regimens" @default.
- W4249496640 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.3729" @default.
- W4249496640 hasPublicationYear "2004" @default.
- W4249496640 type Work @default.
- W4249496640 citedByCount "0" @default.
- W4249496640 crossrefType "journal-article" @default.
- W4249496640 hasAuthorship W4249496640A5017461185 @default.
- W4249496640 hasAuthorship W4249496640A5018888045 @default.
- W4249496640 hasAuthorship W4249496640A5039996765 @default.
- W4249496640 hasAuthorship W4249496640A5058524932 @default.
- W4249496640 hasAuthorship W4249496640A5064011743 @default.
- W4249496640 hasAuthorship W4249496640A5078640497 @default.
- W4249496640 hasAuthorship W4249496640A5088372569 @default.
- W4249496640 hasConcept C121608353 @default.
- W4249496640 hasConcept C126322002 @default.
- W4249496640 hasConcept C143998085 @default.
- W4249496640 hasConcept C2780259306 @default.
- W4249496640 hasConcept C2780962732 @default.
- W4249496640 hasConcept C526805850 @default.
- W4249496640 hasConcept C71924100 @default.
- W4249496640 hasConceptScore W4249496640C121608353 @default.
- W4249496640 hasConceptScore W4249496640C126322002 @default.
- W4249496640 hasConceptScore W4249496640C143998085 @default.
- W4249496640 hasConceptScore W4249496640C2780259306 @default.
- W4249496640 hasConceptScore W4249496640C2780962732 @default.
- W4249496640 hasConceptScore W4249496640C526805850 @default.
- W4249496640 hasConceptScore W4249496640C71924100 @default.
- W4249496640 hasIssue "14_suppl" @default.
- W4249496640 hasLocation W42494966401 @default.
- W4249496640 hasOpenAccess W4249496640 @default.
- W4249496640 hasPrimaryLocation W42494966401 @default.
- W4249496640 hasRelatedWork W114012669 @default.
- W4249496640 hasRelatedWork W2000578400 @default.
- W4249496640 hasRelatedWork W2037724349 @default.
- W4249496640 hasRelatedWork W2050348440 @default.
- W4249496640 hasRelatedWork W2069668461 @default.
- W4249496640 hasRelatedWork W2086063692 @default.
- W4249496640 hasRelatedWork W2352031239 @default.
- W4249496640 hasRelatedWork W2363674970 @default.
- W4249496640 hasRelatedWork W2412467430 @default.
- W4249496640 hasRelatedWork W2940357394 @default.
- W4249496640 hasVolume "22" @default.
- W4249496640 isParatext "false" @default.
- W4249496640 isRetracted "false" @default.
- W4249496640 workType "article" @default.